BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30993437)

  • 1. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
    Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
    Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
    Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
    Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
    Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
    Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
    Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
    Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
    Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
    Grazioli L; Morana G; Kirchin MA; Schneider G
    Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hepatobiliary phase liver MRI versus Contrast-Enhanced Ultrasound after an inconclusive extracellular gadolinium-based contrast-enhanced MRI for the diagnosis of benign hepatocellular tumors.
    Tselikas L; Pigneur F; Roux M; Baranes L; Costentin C; Roche V; Calderaro J; Herin E; Laurent A; Zafrani E; Azoulay D; Mallat A; Rahmouni A; Luciani A
    Abdom Radiol (NY); 2017 Mar; 42(3):825-832. PubMed ID: 27704147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
    AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of focal nodular hyperplasia and hepatocellular adenoma using qualitative and quantitative imaging features and classification and regression tree analysis.
    Alamri TM; Cerny M; Al Shaikh M; Billiard JS; Olivié D; Chagnon M; Tang A
    Abdom Radiol (NY); 2023 Mar; 48(3):874-885. PubMed ID: 36528729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
    Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
    Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis.
    Suh CH; Kim KW; Kim GY; Shin YM; Kim PN; Park SH
    Eur Radiol; 2015 Apr; 25(4):950-60. PubMed ID: 25537979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
    Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
    AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
    [No Abstract]   [Full Text] [Related]  

  • 16. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
    Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
    Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.
    Grazioli L; Morana G; Federle MP; Brancatelli G; Testoni M; Kirchin MA; Menni K; Olivetti L; Nicoli N; Procacci C
    Radiology; 2001 Dec; 221(3):731-9. PubMed ID: 11719669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
    Grazioli L; Morana G; Kirchin MA; Caccia P; Romanini L; Bondioni MP; Procacci C; Chiesa A
    J Magn Reson Imaging; 2003 May; 17(5):593-602. PubMed ID: 12720270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.
    Bonatti M; Valletta R; Zamboni GA; Lombardo F; Senoner M; Simioni M; Schifferle G; Bonatti G
    Eur Radiol; 2019 Jun; 29(6):2830-2836. PubMed ID: 30643946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI.
    Denecke T; Steffen IG; Agarwal S; Seehofer D; Kröncke T; Hänninen EL; Kramme IB; Neuhaus P; Saini S; Hamm B; Grieser C
    Eur Radiol; 2012 Aug; 22(8):1769-75. PubMed ID: 22437921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.